We are so excited to share that Scott Lauder, PhD has joined Auregen as Interim Chief Technical Officer. Scott’s depth of experience as a technical executive in groundbreaking biologic and cell therapy modalities is a great addition to our team as we advance our clinical program for AUR-201 in Microtia.
About us
Auregen Biotherapeutics
- Website
-
http://auregen.bio
External link for Auregen BioTherapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
Locations
-
Primary
Get directions
55 Cambridge Parkway
Suite 401
Cambridge, Massachusetts 02142, US
-
Get directions
Aspenhaustraße 25
Reutlingen, Baden-Württemberg 72770, DE
Employees at Auregen BioTherapeutics
-
Jason Meyenburg
-
Richard Davies
Deputy Chairman of the Board Alvotech | Chairman Immodulon Therapeutics | Managing Partner Gybeset BioConsult GmbH
-
Peter W. Agnes III, CFA
Chief Operating Officer | Operating Partner | Board Member
-
Fereydoun Firouz
Biopharmaceutical & Healthcare | CEO | Board | Transformation & Growth | Entrepreneur | Global
Updates
-
We are excited that our Phase 1/2 open-label study of AUR-201 in Microtia is actively enrolling. Happy to have had our own Pete Weber, CMO, with the team from Dr Thomas Romo III’s office this past week. www.clintrials.gov clintrials@auregen.bio #microtia #goauregenators
-